Cannara Closes $2.8M Buyout of Medican Organic, Tying Off 2021 Quebec Deal

Cannara Biotech (LOVE.TO ) has closed an all-cash deal to acquire every outstanding share of Medican Organic Inc., the Quebec licensed producer announced this week. The C$2.8 million purchase price ties up loose ends from a 2021 transaction that gave Cannara its second cultivation site, and folds Medican’s residual operational know-how — refined cultivation procedures, post-harvest practices, and proprietary extract manufacturing methods — fully into Cannara’s books.

Medican was a wholly owned subsidiary of BZAM Ltd., the Canadian licensed producer whose predecessor entity, The Green Organic Dutchman, originally sold Cannara the Valleyfield site in 2021. The closing followed Medican’s exit from proceedings under the Companies’ Creditors Arrangement Act, the federal restructuring statute that BZAM’s corporate group entered. For Cannara, the deal absorbs a counterparty that no longer functions as a going concern and removes residual exposure inside a creditor process the company did not control.

What the deal locks in

In June 2021, Cannara paid $27 million in cash plus roughly $5.7 million of deposit funding for Medican’s Valleyfield cultivation and manufacturing facility — a one-million-square-foot hybrid greenhouse outside Montreal that Cannara has spent the last several years scaling up into its main production site. That earlier transaction transferred the physical asset; Medican Organic, the legal entity, stayed inside the parent’s corporate structure.

The new deal absorbs the remaining shell. According to Cannara, the transaction completes the 2021 acquisition by bringing Medican’s continued refinements to cultivation practices, post-harvest workflows and extract manufacturing into day-to-day operations alongside the underlying facility.

The C$2.8 million paid for the entity is small by recent multi-state operator deal standards. It also lands at a steep discount to the 2021 facility price tag, reflecting both BZAM’s distressed posture and the fact that the bulk of asset value transferred to Cannara five years ago. The current transaction is best read not as a “discount on the same asset” but as the cleanup of a residual structural overhang from a foundational deal struck in a different cycle of the Canadian cannabis market.

Consolidation at distressed valuations

The deal fits a broader pattern of Canadian licensed producers picking up cultivation capacity from distressed sellers at a fraction of original valuations. BZAM’s corporate group entered CCAA after years of accumulated losses and impairments across the former TGOD assets, freeing up subsidiaries that had been stranded inside the holding-company structure for buyers willing to take on the remaining liabilities.

That dynamic is broader than this single transaction. Larger Canadian and global producers have spent recent quarters acquiring smaller European and Canadian cultivators with similar logic: the assets are operationally functional, the original equity holders have already been written down, and the buyer pays for the operating capacity rather than the historical valuation. The same week as the Cannara closing, Curaleaf finalised the buyout of the remaining 45% stake in Germany’s Four 20 Pharma — a transaction structured around the same template at multi-state-operator scale.

For Cannara, the strategic logic is straightforward: the company already runs Valleyfield as its main production site and benefits from owning the supporting corporate vehicle outright. The closing eliminates a counterparty relationship that no longer serves either side and consolidates the operational IP accumulated since 2021 onto one balance sheet.

Cannara operates two Quebec facilities — Farnham and Valleyfield — totalling more than 1.6 million square feet, with potential annualized cultivation output of 100,000 kg. The company says it holds the top retail market share in Quebec, the country’s second-largest provincial cannabis market, and has reported operating profits in recent quarters — a position that distinguishes it from larger Canadian peers like Canopy Growth (CGC ) and Aurora Cannabis (ACB ), which have spent the post-legalization period working through deeper losses.

What changes operationally

Cannara also confirmed an executive transition: Nicholas Sosiak, its chief financial officer since 2020, moved to chief operating officer effective April 23, 2026. Founder and chief executive Zohar Krivorot framed the change as a recognition of Sosiak’s execution track record. The company is searching for a CFO successor.

Sosiak has been the public face of Cannara’s financial strategy throughout the Valleyfield buildout, including the 2021 private placements used to finance the facility purchase. MyCannabis spoke with him about the company’s growth playbook in a 2022 interview.

The Medican closing tightens Cannara’s corporate structure ahead of an ongoing Valleyfield expansion the company has flagged in recent quarterly disclosures. The next signal to watch is whether the consolidation produces any operational synergies or one-time accounting effects in fiscal Q3 results. Beyond that, the deal is administrative: the assets are already running, the brands are already in market, and the corporate plumbing is now cleaner.